research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
Search
for
Sort by
Research
180-210 / 1000+ results
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
research 2-Substituted 4-(Thio)chromenone 6-O-Sulfamates: Potent Inhibitors of Human Steroid Sulfatase
New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
research Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
research In Silico Screening of DrugBank Compounds as Potential Inhibitors for Human Steroid 5α-Reductase 2 for Androgen-Related Diseases
Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
research 801 TEC family kinase inhibitors as a novel class of therapeutics in alopecia areata
ITK inhibitors may effectively treat alopecia areata.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
research Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
research Titagen® for total wellness: results from a randomised, placebo controlled clinical study on adults for osteoarthritis, improvement in skin, nail and health
Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
Ritlecitinib works well and is safe for treating alopecia areata.
research Treatment of resistant alopecia areata with tofacitinib
Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research 5PSQ-117 Effectiveness of baricitinib in alopecia areata
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.